Insmed
INSM
114 hedge funds and large institutions have $970M invested in Insmed in 2017 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 43 increasing their positions, 30 reducing their positions, and 9 closing their positions.
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
43% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 30
14% more funds holding
Funds holding: 100 → 114 (+14)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.86% less ownership
Funds ownership: 91.9% → 91.04% (-0.86%)
3% less capital invested
Capital invested by funds: $998M → $970M (-$28.3M)
71% less call options, than puts
Call options by funds: $6.39M | Put options by funds: $21.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$28.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$9.2M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$8.11M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$4.6M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$4.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.77M |
| 2 |
JP Morgan Chase
New York
|
-$8.04M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$7.9M |
| 4 |
O
OrbiMed
New York
|
-$7.13M |
| 5 |
Morgan Stanley
New York
|
-$2.32M |
INSM Hedge Fund Activity: Q2 2017 in Review
114 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q2 2017, worth a combined $970M — down 2.8% from $998M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new INSM positions and 9 closed out — a net gain of 15 holders — while 43 added to existing stakes and 30 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $28.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.77M.
- 114 institutional investors held Insmed (INSM) as of Q2 2017, up from 100 in Q1 2017.
- Funds reported $970M of Insmed stock for Q2 2017, down 2.8% quarter-over-quarter.
- 24 funds opened new Insmed positions in Q2 2017 and 9 closed out, a net change of +15 holders.
- The largest Insmed buyer in Q2 2017 was Janus Henderson Group, an estimated $28.2M added.
- The largest Insmed seller in Q2 2017 was T. Rowe Price Associates, an estimated $8.77M sold.
Based on aggregated 13F filings for Q2 2017.